Skip to main content

Table 4 Baseline features of the participants

From: Adverse drug events observed in patients with type 2 diabetes mellitus treated with 100 mg versus 300 mg canagliflozin: a systematic review and meta-analysis of published randomized controlled trials

Trials Mean age (y) Males (%) HbA1c (%) Duration (y) BMI (kg/m2)
  100/300 mg 100/300 mg 100/300 mg 100/300 mg 100/300 mg
Blonde 2016 [9] 56.4/55.8 52.2/49.7 7.8/7.8 6.5/6.7 31.0/31.2
Forst 2014 [10] 56.7/57.0 68.1/55.3 8.0/7.9 10.5/11.0 32.3/32.8
Neal 2015 [11] 62.0/63.0 67.0/65.0 8.3/8.3 16.4/16.3 33.0/33.3
Gonzalez 2013 [12] 55.5/55.3 47.3/45.0 7.9/7.9 6.7/7.1 32.4/31.4
Inagaki 2013 [13] 57.7/57.1 70.3/73.3 8.05/8.17 - 25.6/25.9
Stenlof 2013 [15] 55.1/55.3 41.5/45.2 8.1/8.0 4.5/4.3 31.3/31.7
Wilding 2013 [16] 57.4/56.1 48.4/55.8 8.1/8.1 9.0/9.4 33.3/33.2
Yale 2013 [17] 69.5/67.9 64.4/53.9 7.9/8.0 15.6/17.0 32.4/33.4
Rosenstock 2012 [18] 51.7/52.3 56.0/56.0 7.8/7.7 6.1/5.9 31.7/31.6
  1. Abbreviations: y year, HbA1c glycosylated hemoglobin, BMI body mass index, Duration referred to duration of type 2 diabetes mellitus
  2. 100 and 300 mg were referred to canagliflozin dosage